Radiopharm Theranostics (NASDAQ:RADX) Earns Buy Rating from B. Riley

Posted by ABMN Staff on Dec 18th, 2025

Radiopharm Theranostics (NASDAQ:RADX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at B. Riley in a note issued to investors on Tuesday,Benzinga reports. They presently have a $16.00 price target on the stock, up from their prior price target of $13.00. B. Riley’s price target would indicate a potential upside of 199.63% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Radiopharm Theranostics has an average rating of “Buy” and an average target price of $15.33.

Read Our Latest Analysis on Radiopharm Theranostics

Radiopharm Theranostics Price Performance

Shares of NASDAQ RADX opened at $5.34 on Tuesday. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25. The business has a 50-day simple moving average of $5.26 and a two-hundred day simple moving average of $5.24.

Hedge Funds Weigh In On Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) by 100.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 16,000 shares of the company’s stock after purchasing an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned approximately 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent quarter.

Radiopharm Theranostics Company Profile

(Get Free Report)

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.